1. Scrip
  2. >>Advanced Therapies
  3. >>Gene Therapies

Sarepta Sinks On Mixed DMD Gene Therapy Study

Blames 'Bad Luck In Randomization Process'

 
• By Kevin Grogan

Any time advantage Sarepta's Duchenne muscular dystrophy gene therapy may have had over rivals, notably Pfizer, has disappeared after SRP-9001 failed to significantly improve muscle function in a closely watched trial.

dmd
Dystrophin is the protein missing in children born with DMD • Source: Shutterstock

Shares in Sarepta Therapeutics, Inc. have slid after a keenly anticipated study showed that SRP-9001, its investigational gene therapy for Duchenne muscular dystrophy (DMD), failed to significantly improve muscle function, dealing a blow to hopes that the one-time treatment would get approval for the devastating childhood disease any time soon.

Sarepta has unveiled top-line results from the first part of the 41-patient Study 102, the first placebo-controlled trial of SRP-9001,...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from Gene Therapies

Rocket’s Warp Drive Back Online As FDA Lifts Danon Gene Therapy Hold

 
• By Alaric DeArment

The company took a prophylactic C3 inhibitor out of the immunomodulatory regimen used in its Phase II study of RP-A501, lowered the dose and adjusted its use of eculizumab.

DMD Plans Remain Central For Regenxbio Despite Hunter Syndrome FDA Approval Delay

 
• By Manas Mishra

All eyes will be on Regenxbio's DMD data, expected next year, as the drug developer navigates a three-month delay to its FDA approval hopes for its Hunter syndrome gene therapy.

Sarepta Will Resume US Elevidys Shipments For Ambulatory DMD Patients

 
• By Mandy Jackson

The FDA recommended removal of a voluntary hold on shipments of the gene therapy to younger patients after finding that the death of an 8-year-old boy in Brazil was unrelated to Elevidys.

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 
• By Alexandra Shimmings

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.

More from Advanced Therapies

China’s BRL Gears Up For First UCAR-T Trial In Leukemia/Lymphoma

 
• By Xu Hu

Shanghai-based BRL Medicine is building a novel pipeline led by universal CAR-Ts. Its founder talks to Scrip about the benefits of this approach, China's potential advantages in the field and challenges faced by new ventures.

Competition Weighs On Gilead’s CAR-Ts As Both See Sales Decline

 
• By Alaric DeArment

The quarter saw strong growth overall, but the company now expects sales of Yescarta and Tecartus to fall for the full year 2025 versus 2024 thanks to competition.

Sumitomo Parkinson’s Filing A Pivotal Moment For Japan’s iPSC Ambitions

 
• By Lisa Takagi

Sumitomo Pharma's iPSC therapy for Parkinson's has been filed for approval in Japan after showing safety and efficacy in a Phase I/II trial and may become one of the first such therapies to reach the market in the country, which has invested heavily in the modality.